Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases

Cannot have received: intrathecal therapy

Exception: Prior intrathecal therapy allowed if given ≥14 days before study registration

Intrathecal therapy given less than 14 days before study registration

Cannot have received: intrathecal therapy

Concurrent intrathecal therapy

Cannot have received: systemically delivered therapy

Exception: Allowed if LM develops while on systemic therapy AND systemic therapy is NOT associated with more than grade 1 myelosuppression

Systemically delivered therapy UNLESS LM develops while on systemically delivered therapy AND the systemically delivered therapy is NOT associated with more than grade 1 myelosuppression

Cannot have received: systemically delivered therapy

Exception: Prior systemic therapy allowed if given ≥28 days before study registration

Systemically delivered therapy given less than 28 days before study registration

Cannot have received: whole brain radiation therapy

Exception: Prior spinal cord/cauda equina or partial brain/SRS allowed under specified dose/timing conditions

Patients who had any therapeutic radiation dose to the whole brain regardless of when the radiation treatment was delivered, except: Prior radiation dose to the spinal cord and/or cauda equina is allowed if the equivalent dose in 2 Gy fractions (EQD2) was ≤ 30 Gy to the spinal cord and/or cauda equina using α/β ratio of 3 and if prior radiotherapy has been > 14 days and ≤ 6 months, or was ≤45 Gy to the spinal cord and/or cauda equina using α/β ratio of 3 and if prior radiotherapy has been > 6 months. Prior stereotactic radiosurgery (SRS) to the brain or partial brain radiotherapy is allowed if the equivalent dose in 2 Gy fractions (EQD2) was ≤ 30 Gy to brainstem and/or optic structures (optic nerves, optic chiasm) using α/β ratio of 3 and if prior radiotherapy has been > 14 days and ≤ 6 months, or was ≤ 45 Gy to the brainstem and/or optic structures (optic nerves, optic chiasm) using α/β ratio of 3 and if prior radiotherapy has been > 6 months.